Table 1.
Baseline characteristics.
| Characteristics | All patients (n = 400) |
|---|---|
| Sex | |
| Female | 325(81.25%) |
| Male | 75(18.75%) |
| Age | |
| ≤45 | 284(71.00%) |
| >45 | 116(29.00%) |
| BMI | |
| <25 | 202(50.50%) |
| ≥25 | 198(49.50%) |
| Hashimoto’s thyroiditis | |
| YES | 117(29.25%) |
| NO | 283(70.75%) |
| Focality | |
| Multifocal | 106(26.50%) |
| Unifocal | 294(73.50%) |
| Size | |
| <1cm | 319(79.75%) |
| ≥1cm | 81(20.25%) |
| Central lymph node metastasis | |
| YES | 140(35.00%) |
| NO | 260(65.00%) |
| Capsular invasion | |
| YES | 21(5.25%) |
| NO | 379(94.75%) |
| BRAF | |
| (+) | 316(79.00%) |
| (-) | 84(21.00%) |
| FT3 | 4.19 ± 0.53 |
| FT4 | 11.89 ± 4.13 |
| TSH | 2.33 ± 1.87 |
| CEA | 1.69 ± 3.17 |
| Surgical Procedures | |
| pCCND (cN0) | 190(47.50%) |
| tCCND (cN1) | 210(52.50%) |
BMI, Body Mass Index; FT3, free triiodothyronine; FT4, free thyroxin; TSH, thyroid stimulating hormone; CEA, carcinoembryonic antigen; pCCND, Preventive Central Lymph Node Dissection; tCCND, therapeutic Central lymph node dissection.